AAS
VRCA icon

Ameritas Advisory Services’s Verrica Pharmaceuticals VRCA Stock Holding History

Ameritas Advisory Services’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184 Buy
+30
New +$187 ﹤0.01% 1897
2025
Q3 		– Sell
-30
Closed -$159 – 2920
2025
Q2 		$159 Buy
+30
New +$161 ﹤0.01% 2773

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ameritas Advisory Services's VRCA Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in Verrica Pharmaceuticals (VRCA) in Q2 2026: 30 shares worth $184. The stake represents ﹤0.01% of the portfolio and ranks #1897 among its holdings. This is a return to the name: Ameritas Advisory Services previously reported a position in VRCA as recently as Q2 2025.

Ameritas Advisory Services first reported a position in VRCA in Q2 2025 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Ameritas Advisory Services held 30 shares of Verrica Pharmaceuticals worth $184 as of Q2 2026.
  • Verrica Pharmaceuticals was a new Ameritas Advisory Services position in Q2 2026.
  • Verrica Pharmaceuticals made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1897 holding.
  • Ameritas Advisory Services first reported a position in Verrica Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.